{
    "clinical_study": {
        "@rank": "36919", 
        "acronym": "GZH-001", 
        "arm_group": [
            {
                "arm_group_label": "A", 
                "arm_group_type": "Experimental", 
                "description": "Capecitabine: 1000mg/m^2 bid, days 1-14, every 3 weeks until progression/intolerance."
            }, 
            {
                "arm_group_label": "B", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Observation until progression"
            }
        ], 
        "brief_summary": {
            "textblock": "To confirm the efficacy and safety of XELOX with capecitabine maintenance in treatment of\n      advanced gastric cancer (AGC)"
        }, 
        "brief_title": "The Maintenance Therapy of Capecitabine of Advanced Gastric Cancer", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 18 years old\n\n          -  male or female\n\n          -  Patients with stage IV gastric cancer by pathology or cytology and imaging diagnosis\n             , or after previous surgery or radiotherapy or chemotherapy in patients with stage IV\n             gastric cancer progression , there RECIST criteria evaluable lesions ;\n\n          -  ECOG performance status score 0-2 ;\n\n          -  Expected survival time more than three months ;\n\n          -  Adequate hematologic parameters and liver and kidney function ;\n\n          -  Bone marrow : absolute neutrophil count (ANC) \u2265 1.5 \u00d7 109 / L, platelets \u2265 75 \u00d7 109 /\n             L, hemoglobin \u2265 80g / L;\n\n          -  Liver: bilirubin \u2264 1.5 times the upper limit of normal , ALT AST values \u200b\u200b\u2264 2.5 times\n             the upper limit of normal ;\n\n          -  Renal : serum creatinine \u2264 ULN ;\n\n          -  Informed consent of patients or their agents , and signed informed consent.\n\n        Exclusion Criteria:\n\n          -  For patients allergic to capecitabine ;\n\n          -  Patients with CNS metastases\n\n          -  Undermine the integrity of the upper gastrointestinal tract , malabsorption syndrome\n             , or unable to take oral medication ;\n\n          -  Patients with coronary heart disease , angina , myocardial infarction , arrhythmia,\n             cerebral thrombosis, stroke and other serious cardiovascular and cerebrovascular\n             disease ;\n\n          -  Or in combination with other anti-tumor therapy in patients participating in clinical\n             trials of other interventions ;\n\n          -  Pregnancy or breast-feeding patients , or fertility without taking adequate\n             contraceptive measures were ;\n\n          -  The researchers believe that this test is not suitable for those who participate ."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "224", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02038621", 
            "org_study_id": "2ndSichuan", 
            "secondary_id": "GZH-001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "A", 
                    "B"
                ], 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "A", 
                    "B"
                ], 
                "description": "Before randomization,all enrolled patients underwent 3 cycles XELOX chemotheray. After patients' disease achieved CR\\PR\\SD,then randomized into this clinical trial.", 
                "intervention_name": "Oxaliplatin and Capecitabine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxaliplatin", 
                "Capecitabine", 
                "Paclitaxel", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 15, 2014", 
        "number_of_arms": "2", 
        "official_title": "Phase II Clinical Study of the Maintenance Therapy of Capecitabine Afer the XELOX in Treatment of Advanced Gastric Cancer", 
        "overall_contact": {
            "email": "yaya713913@126.com", 
            "last_name": "Chengya Zhou, bachelor", 
            "phone": "86 13980972569"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression Free Survival (PFS)", 
            "safety_issue": "Yes", 
            "time_frame": "From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02038621"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The Second People's Hospital of Sichuan", 
            "investigator_full_name": "Chengya Chou", 
            "investigator_title": "Oncology physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "overall survival (OS)", 
                "safety_issue": "Yes", 
                "time_frame": "from the date of randomization until death from any cause or up to 1 year"
            }, 
            {
                "measure": "adverse events (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "from date of randomization to 28 days after the last chemo dosage"
            }, 
            {
                "measure": "health-related quality of life (HRQOL", 
                "safety_issue": "No", 
                "time_frame": "evaluate every 6 weeks from the date of randomization until 28 days after the last chemo dosage"
            }
        ], 
        "source": "The Second People's Hospital of Sichuan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The Second People's Hospital of Sichuan", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}